FPR1 and cancer: Currently, the FPR family represents an interesting pharmacological target for the treatment of some pathologies, such as inflammatory lung diseases, ischemia–reperfusion injury, neuroinflammation, and cancer (Bozinovski et al., 2013; Burli et al., 2006; Cussel et al., 2019; Huang et al., 2009; Liu et al., 2014; Maris, 2010; Perretti et al., 2015; Prevete et al., 2005, 2015; Snapkov et al., 2016; Xiang et al., 2016).